The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Pharmacokinetics and Safety of AMD-3100, a Novel Antagonist of the CXCR-4 Chemokine Receptor, in Human Volunteers
Open accessAbstract
AMD-3100, a bicyclam, is a novel agent that uniquely inhibits the entry of human immunodeficiency virus type 1 (HIV-1) into CD4 + T cells via selective blockade of the chemokine CXCR-4 receptor. Twelve healthy volunteers were given AMD-3100 as a single 15-min intravenous infusion at 10, 20, 40, or 80 μg/kg. Five subjects also received a single subcutaneous injection of AMD-3100 (40 or 80 μg/kg). Three subjects received two escalating oral doses each (80 and 160 μg/kg). All subjects tolerated their dose(s) well without any grade 2 toxicity or dose adjustment. Six subjects experienced mild, transient symptoms, primarily gastrointestinal in nature and not dose related. All subjects experienced a dose-related elevation of the white blood cell count, from 1.5 to 3.1 times the baseline, which returned to the baseline 24 h after dosing. AMD-3100 demonstrated dose proportionality for the maximum drug concentration in serum ( C max ) and the area under the concentration-time curve from 0 h to ∞ (AUC 0–∞ ) over the entire dose range. At the highest intravenous dose (80 μg/kg), the median C max was 515 (range, 470 to 521) ng/ml and the AUC 0–∞ was 1,044 (range, 980 to 1,403) ng-h/ml. The median systemic absorption after subcutaneous dosing was 87% (range, 67 to 106%). No drug was detectable in the blood following oral dosing. Using a two-compartment model, the median pharmacokinetic parameter estimates (ranges) were as follows: volume of distribution, 0.34 (0.27 to 0.36) liter/kg; clearance, 1.30 (0.97 to 1.34) liters/h; elimination half-life, 3.6 (3.5 to 4.9) h. After a single, well-tolerated intravenous dose of AMD-3100, concentrations were sustained for 12 h above the in vitro antiretroviral 90% inhibitory concentrations and for 8 h above antiviral concentrations identified in the SCID-hu Thy/Liv mouse model of HIV infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of a major co-receptor for primary isolates of HIV-1
Deng, H., Liu, R., Ellmeier, W., Choe, S., Unutmaz, D., Burkhart, M., Marzio, P. D., Marmon, S., Sutton, R. E., Hill, C. M., et al. (1996) · Nature · doi:10.1038/381661a0 · Cited by 3,641
HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5
Dragic, T., Litwin, V., Allaway, G. P., Martin, S. R., Huang, Y., Nagashima, K. A., Cayanan, C., Maddon, P. J., Koup, R. A., Moore, J. P., et al. (1996) · Nature · doi:10.1038/381667a0 · Cited by 3,174
Cocchi, F., DeVico, A. L., Garzino-Demo, A., Arya, S. K., Gallo, R. C., & Lusso, P. (1995) · Science · doi:10.1126/science.270.5243.1811 · Cited by 2,869
Chemokines and leukocyte traffic
Baggiolini, M. (1998) · Nature · doi:10.1038/33340 · Cited by 2,709
CC CKR5: A RANTES, MIP-1α, MIP-1β Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1
Alkhatib, G., Combadiere, C., Broder, C. C., Feng, Y., Kennedy, P. E., Murphy, P. M., & Berger, E. A. (1996) · Science · doi:10.1126/science.272.5270.1955 · Cited by 2,706
Dependence of Human Stem Cell Engraftment and Repopulation of NOD/SCID Mice on CXCR4
Peled, A., Petit, I., Kollet, O., Magid, M., Ponomaryov, T., Byk, T., Nagler, A., Ben-Hur, H., Many, A., Shultz, L., et al. (1999) · Science · doi:10.1126/science.283.5403.845 · Cited by 1,644
A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1)
Bleul, C. C., Fuhlbrigge, R. C., Casasnovas, J. M., Aiuti, A., & Springer, T. A. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.3.1101 · Cited by 1,482
Aiuti, A., Webb, I. J., Bleul, C., Springer, T., & Gutierrez-Ramos, J. C. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.1.111 · Cited by 1,158
Schuitemaker, H., Koot, M., Kootstra, N. A., Dercksen, M. W., de Goede, R. E., van Steenwijk, R. P., Lange, J. M., Schattenkerk, J. K., Miedema, F., & Tersmette, M. (1992) · Journal of Virology · doi:10.1128/jvi.66.3.1354-1360.1992 · Cited by 1,032
AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor
Donzella, G. A., Schols, D., Lin, S. W., Esté, J. A., Nagashima, K. A., Maddon, P. J., Allaway, G. P., Sakmar, T. P., Henson, G., DeClercq, E., et al. (1998) · Nature Medicine · doi:10.1038/nm0198-072 · Cited by 760
Self-citationTersmette, M., de Goede, R. E., Al, B. J., Winkel, I. N., Gruters, R. A., Cuypers, H. T., Huisman, H. G., & Miedema, F. (1988) · Journal of Virology · doi:10.1128/jvi.62.6.2026-2032.1988 · Cited by 595
Inhibition of T-tropic HIV Strains by Selective Antagonization of the Chemokine Receptor CXCR4
Schols, D., Struyf, S., Damme, J. V., Esté, J. A., Henson, G., & Clercq, E. D. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.8.1383 · Cited by 554
Self-citationDistinct replicative and cytopathic characteristics of human immunodeficiency virus isolates
Fenyö, E. M., Morfeldt-Månson, L., Chiodi, F., Lind, B., von Gegerfelt, A., Albert, J., Olausson, E., & Asjö, B. (1988) · Journal of Virology · doi:10.1128/jvi.62.11.4414-4419.1988 · Cited by 433
Hesselgesser, J., Taub, D., Baskar, P., Greenberg, M., Hoxie, J., Kolson, D. L., & Horuk, R. (1998) · Current Biology · doi:10.1016/s0960-9822(98)70230-1 · Cited by 408
Chemokine Receptors in Human Endothelial Cells
Gupta, S. K., Lysko, P. G., Pillarisetti, K., Ohlstein, E., & Stadel, J. M. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.7.4282 · Cited by 407
Zaitseva, M., Blauvelt, A., Lee, S., Lapham, C. K., Kiaus-Kovrun, V., Mostowski, H., Manischewitz, J., & Golding, H. (1997) · Nature Medicine · doi:10.1038/nm1297-1369 · Cited by 389 · cited 1×
“Whereas the most commonly transmitted strains are those with the macrophage-tropic, non-syncytium-inducing phenotype which utilize CCR5 for entry, the T-tropic, syncytium-inducing strains that use CXCR4 are rarely transmitted (15, 29, 34).”
BackgroundSimmons, G., Wilkinson, D., Reeves, J. D., Dittmar, M. T., Beddows, S., Weber, J., Carnegie, G., Desselberger, U., Gray, P. W., Weiss, R. A., et al. (1996) · Journal of Virology · doi:10.1128/jvi.70.12.8355-8360.1996 · Cited by 360
Hesselgesser, J., Halks-Miller, M., DelVecchio, V., Peiper, S. C., Hoxie, J., Kolson, D. L., Taub, D., & Horuk, R. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00055-8 · Cited by 324
De Clercq, E., Yamamoto, N., Pauwels, R., Balzarini, J., Witvrouw, M., De Vreese, K., Debyser, Z., Rosenwirth, B., Peichl, P., & Datema, R. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.4.668 · Cited by 296
Chemokines and Chemokine Receptors: Biology and Clinical Relevance in Inflammation and AIDS
Locati, M., & Murphy, M. (1999) · Annual Review of Medicine · doi:10.1146/annurev.med.50.1.425 · Cited by 283
Wong, J. K., Ignacio, C. C., Torriani, F., Havlir, D., Fitch, N. J., & Richman, D. D. (1997) · Journal of Virology · doi:10.1128/jvi.71.3.2059-2071.1997 · Cited by 281
Connor, R. I., & Ho, D. D. (1994) · Journal of Virology · doi:10.1128/jvi.68.7.4400-4408.1994 · Cited by 259
Lavi, E., Strizki, J., Ulrich, A. M., Zhang, W., Fu, L., Wang, Q., O’Connor, M. J., Hoxie, J. A., & González‐Scarano, F. (1997) · Europe PMC (PubMed Central) · Cited by 237
Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor Fusin/CXCR-4
Schols, D., Esté, J. A., Henson, G., & De Clercq, E. (1997) · Antiviral Research · doi:10.1016/s0166-3542(97)00025-9 · Cited by 220
Self-citationLabrosse, B., Brelot, A., Heveker, N., Sol‐Foulon, N., Schols, D., Clercq, E. D., & Alizon, M. (1998) · Journal of Virology · doi:10.1128/jvi.72.8.6381-6388.1998 · Cited by 142
Chemokine Receptor CXCR4 Expression in Endothelium
Volin, M. V., Joseph, L. J., Shockley, M. S., & Davies, P. F. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.7890 · Cited by 125
DATEMA, R., Rabin, L. B., Hincenbergs, M., Moreno, M. B., Warren, S., Linquist-Stepps, V. D., Rosenwirth, B., SEIFERT, J. ‐., & McCune, J. M. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.3.750 · Cited by 102
Esté, J. A., Cabrera, C., Clercq, E. D., Struyf, S., Damme, J. V., Bridger, G. J., Skerlj, R. T., Abrams, M. J., Henson, G. W., Gutiérrez, A., et al. (1999) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)23157-6 · Cited by 101
Self-citationChemokine receptor antagonists: novel therapeutics for inflammation and AIDS
Ponath, P. D. (1998) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.7.1.1 · Cited by 39
Viardot, A., Kronenwett, R., Deichmann, M., & Haas, R. R. (1998) · Annals of Hematology · doi:10.1007/s002770050442 · Cited by 38
Cited by
Involvement of chemokine receptors in breast cancer metastasis
Müller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S. N., et al. (2001) · Nature · doi:10.1038/35065016 · Cited by 5,340
Synthetic therapeutic peptides: science and market
Vlieghe, P., Lisowski, V., Martinez, J., & Khrestchatisky, M. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2009.10.009 · Cited by 1,476
G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4
Petit, I., Szyper-Kravitz, M., Nagler, A., Lahav, M., Peled, A., Habler, L., Ponomaryov, T., Taichman, R. S., Arenzana-Seisdedos, F., Fujii, N., et al. (2002) · Nature Immunology · doi:10.1038/ni813 · Cited by 1,332
In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment
Sipkins, D. A., Wei, X., Wu, J. W., Runnels, J. M., Côté, D., Means, T. K., Luster, A. D., Scadden, D. T., & Lin, C. P. (2005) · Nature · doi:10.1038/nature03703 · Cited by 878
Martin, C., Burdon, P. C. E., Bridger, G., Gutierrez-Ramos, J.-C., Williams, T. J., & Rankin, S. M. (2003) · Immunity · doi:10.1016/s1074-7613(03)00263-2 · Cited by 770
Self-citation
Metadata
- Authors
- Hendrix, C. W., Flexner, C., MacFarland, R. T., Giandomenico, C., Fuchs, E. J., Redpath, E., Bridger, G., & Henson, G. W.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2000-06
- Volume
- 44
- Issue
- 6
- Pages
- 1667-1673
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2150833007
- Cited by
- 504
- References
- 30
- FWCI
- 16.57
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.